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Abstract
Background—Free radical scavengers have failed to improve patient outcomes promoting the 
concept that clinically important oxidative stress (OS) may be mediated by alternative 
mechanisms. We sought to examine the association of emerging aminothiol markers of non-free
radical mediated oxidative stress with clinical outcomes. 
Methods and Result—Plasma levels of reduced (cysteine and glutathione) and oxidized (cystine 
and glutathione disulphide) aminothiols were quantified by high performance liquid 
chromatography in 1411 patients undergoing coronary angiography (mean age 63 years, male 
66%).  All patients were followed for a mean of 4.7±2.1 years for the primary outcome of all-
cause death (n=247). Levels of cystine (oxidized) and glutathione (reduced) were associated with 
risk of death (p<0.001 both) before and after adjustment for covariates. High cystine and low 
glutathione levels (>+1 SD & <-1 SD respectively) were associated with higher mortality 
(adjusted HR 1.63 (95% CI 1.19-2.21; HR 2.19 (95% CI 1.50-3.19), respectively) compared to 
those outside these thresholds. Furthermore, the ratio of cystine/glutathione was also 
significantly associated with mortality (adjusted HR 1.92 (95% CI 1.39-2.64) and was 
independent of and additive to hs-CRP level.  Similar associations were found for other 
outcomes of cardiovascular death and combined death and myocardial infarction. 
Conclusions—A high burden of OS, quantified by the plasma aminothiols, cystine, glutathione 
and their ratio is associated with mortality in patients with CAD, a finding that is independent of 
and additive to the inflammatory burden.  Importantly, this data supports the emerging role of 
non-free radical biology in driving clinically important oxidative stress.  
Key words: oxidative stress; redox; biomarker; coronary artery disease; mortality; cystine; 
glutathione; prognosis; cardiovascular outcomes; cardiac biomarker 
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Introduction 
Oxidative stress (OS) is implicated in the pathophysiology of multiple conditions including 
cardiovascular disease (CVD).1  Although the harmful cellular effects of free radical species in 
vitro remain undisputed, observational evidence along with clinical trials of free radical 
scavengers has been uniformly disappointing.2, 3  This has promoted the concept that free radicals 
may not constitute clinically important sources of oxidants and that non-free radical species may 
be of equal or greater importance.4   
Proteins are susceptible to oxidation through alterations of reactive aminothiol residues 
such as cysteine and glutathione.  These covalent modifications serve to alter the cellular 
signaling activity of the proteins, thereby coupling redox modifications of aminothiols to 
functional activity.5  Importantly these aminothiols can be quantified in plasma to assess the 
oxidant burden in vivo.6  Of these, cysteine constitutes the major aminothiol pool extracellularly 
that reacts readily with oxidants to form its oxidized disulphide cystine. Intracellularly, 
glutathione is a major antioxidant that helps eliminate peroxides and maintain cellular redox, and 
its oxidized form is glutathione disulfide.4  Increased OS, measured as higher levels of cystine, 
lower levels of glutathione, or altered ratios of oxidized to reduced aminothiols, is associated 
with cellular dysfunction, aging, risk factors for CVD and subclinical vascular disease, and are 
likely to be reliable markers of systemic OS and antioxidant defence.7-13 
However, there remains a need to determine if oxidant burden as indicated by alterations 
in the levels or ratios of these aminothiols is clinically relevant and determines adverse 
outcomes.  This would support the use of these aminothiols as biomarkers of OS and potentially 
promote development of novel anti-oxidant therapies. We thus sought to determine whether the 
major aminothiols and their respective ratios would be associated with increased mortality and 
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cardiovascular events in a prospectively followed high risk population. 
Methods
Study population 
Study participants aged 20-90 years were recruited as part of the Emory Cardiovascular Biobank, 
an ongoing prospective cohort of patients enrolled prior to undergoing coronary angiography for 
investigation or management of CAD across three Emory Healthcare sites with collection of 
extensive data on demographic characteristics, medical history, medication use, behavioral habits 
and risk factor prevalence.14, 15  
Recruited patients were stable at the time of enrollment and undergoing an elective 
procedure, although stable patients with non-ST elevation myocardial infarction, defined using 
international criteria were also included and classified as “Acute MI”.16  Coronary artery disease 
(CAD) burden was quantified using the semi-quantitative Gensini score, as previously 
described.16 Left ventricular function was expressed using ejection fraction (EF).17 Finally 
glomerular filtration rate (GFR) was estimated using the CKD-EPI formula.18 Subjects were 
excluded if they had a history of heart transplantation, recent transfusion, immunosuppressant 
use, malignancy, or significant infections or any vitamin supplements in the previous 6 weeks.  
Specific dietary intake patterns were not documented but blood samples and measurements were 
taken after an overnight fast prior to planned coronary angiography, except in <1% of patients 
who underwent angiography emergently on the same day.   The study was approved by the 
Institutional Review Board at Emory University and all subjects provided written informed 
consent.   
Follow-up and Outcomes 
The cohort was prospectively followed for determination of the primary outcome of all-cause 
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death and the secondary outcomes of cardiovascular death and the composite of death/or non-
fatal MI.  This was performed by personnel blinded to aminothiol data, through telephone 
interview, chart review and linkage with the Social Security Death Index and State records.  
Cardiovascular death was defined as death attributable to an ischemic cardiovascular cause (fatal 
MI, ischemic stroke, peripheral arterial disease) or sudden death due to an unknown but 
presumed cardiovascular cause in high risk CAD patients.  Medical records were accessed or 
requested to validate all self-reported events including MI, which was defined using standard 
criteria as above.16  Fifteen patients (1%) were lost to follow up and were excluded from 
analysis, leaving 1411 patients with complete biomarker and follow-up data. 
Measurement of aminothiols and CRP 
We measured plasma cysteine (CyS), its oxidized form cystine (CySS), glutathione (GSH), and 
its oxidized form glutathione disulphide (GSSG) in all subjects using high performance liquid 
chromatography (HPLC) mass spectrometry. A full methods and protocol paper has been 
published previously outlining sample collection, processing and analysis steps in detail.6    
Summary details are also presented in supplementary materials, but briefly, arterial blood 
samples were drawn via syringe immediately after placement of a femoral arterial sheath (prior 
to heparin or saline flush or any coronary intervention) and transferred into pre-prepared 
Eppendorf tubes containing preservatives to retard auto-oxidation, centrifuged, and stored at 
?80 °C for no more than 2 months prior to transfer to the laboratory.  Sample collection and 
storage conditions in this way have been previously verified.6   Analyses by HPLC were 
performed after dansyl derivatization on a 3-aminopropyl column with fluorescence detection.  
Metabolites were identified by co-elution with standards and quantified by integration relative to 
the internal standard, with validation relative to external standards as previously described.6  
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Ratios of oxidized to reduced aminothiols (cystine/cysteine and glutathione 
disulphide/glutathione) are expressed directly.  The coefficients of variation for each of the 
aminothiols were as follows: cysteine 3.8%; cystine 3.2%; glutathione 5% and glutathione 
disulphide 9.7%.  High sensitivity CRP levels were quantified using a sandwich immunoassay 
(R&D Systems, Minneapolis, Minnesota).  Minimum detectable hs-CRP concentrations were 
0.1mg/l.  
Statistical methods 
Continuous variables are presented as means ± SD or as median (IQR) and categorical variables as 
proportions (%) with one way analysis of variance and chi-squared tests used to determine 
differences between groups.   
Prior to analysis, aminothiol measures were non-normally distributed and were natural log 
+1 transformed. Furthermore, to make the effects comparable between markers, the log-
transformed variables were standardized to have mean 0 and standard deviation (SD) 1. They were 
assessed as continuous and categorical traits, initially by per unit log increase and per SD 
increment and then by a 1x SD cut off to classify “high” and “low” values.  Survival analysis was 
performed using Kaplan Meier curves as well as Cox proportional-hazards regression in models 
adjusted first for age, gender and then additionally for body mass index (BMI; kg/m2), glomerular 
filtration rate (GFR; l/min), presence of diabetes, hypertension, total cholesterol (mg/dl), High 
Density Lipoprotein (HDL; mg/dl), current smoking, statin use, acute MI at enrollment, LV 
function (EF; %), Gensini score and plasma hs-CRP at baseline. Given inflammation and oxidative 
stress are biologically inter-related, an interaction term between hs-CRP and each of the markers 
(including their ratios) was initially included in the model. Interaction between age and each 
marker was also considered to examine any potential age-modifying effects.  Missing covariate 
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data (range 0-3%) was imputed and sensitivity analysis with un-imputed data found results to be 
similar.  The proportional hazards assumption for Cox models was evaluated by plots of 
Schoenfeld residuals and formal testing (a chi-square test calculated as the sum of Schoenfeld 
residuals), with no significant violations of the assumption found.  
The incremental value of the aminothiol markers for risk prediction was tested before and 
after their addition to a clinical model with traditional risk predictors (age, gender, BMI, GFR, 
diabetes, hypertension, total cholesterol, HDL, current smoking, statin use, acute MI, LV 
function, Gensini score).  The C-statistic and category-free net reclassification improvement 
(NRI) as well as integrated discrimination improvement (IDI) that can account for censored data 
were calculated as a measure of risk discrimination.19-22  We set the truncation time at 5 years. 
The resulting risk discrimination metrics indicate the performance of the given model in 
predicting events that occurred in the time range from baseline to 5 years. P values of <0.05 from 
two-sided tests were considered to indicate statistical significance.  Statistical analyses were 
performed using SPSS 20.0 (Chicago, IL), SAS (Cary, NC) and R (3.1.0). 
Results
Baseline characteristics of the 1411 patients are presented in Table 1 and were reflective of a 
typical population recruited at coronary angiography.  The mean age of the cohort was 63.2 
(±11.3) years, 66% male, 32% with diabetes, 69% with hypertension and or hyperlipidemia, and 
16% were current smokers. Approximately 72% had significant CAD (>50% luminal stenosis) 
on angiography, 14% had presented with evidence of acute myocardial infarction (all stable 
NSTEMI), and 46% were treated with revascularization during the admission at which they were 
enrolled, Table 1.  
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Relationship between aminothiols 
The oxidized aminothiol, cystine was almost 8-fold more abundant than its reduced form 
cysteine, while the reduced aminothiol glutathione was 40-times more abundant than its oxidized 
form glutathione disulphide, Table 1. There were modest correlations between the various 
aminothiols, while hs-CRP was only marginally associated with the aminothiol markers 
(Supplementary Table 1).    
Relationship between aminothiols and demographic and clinical features 
In univariate analyses, higher plasma cystine levels (high OS) were associated with older age, 
female gender, higher BMI, impaired renal function (lower GFR), presence of diabetes, 
hypertension, lower total cholesterol levels, statin use, impaired LV function (lower EF), greater 
CAD burden (Gensini), and greater inflammation (hs-CRP).  Of these, only age, gender, BMI, 
GFR, diabetes and hypertension were independently associated with plasma cystine in a 
multivariate model.  Higher glutathione levels (less OS) were associated with younger age, lower 
GFR, absence of diabetes and hypertension, lower CAD burden and higher total cholesterol.  Of 
these only age, GFR, CAD burden, and total cholesterol remained independently associated with 
plasma glutathione.  Higher cysteine levels also correlated independently with GFR, diabetes, 
CAD burden and total cholesterol while glutathione di-sulphide did not show any associations 
aside from an inverse association with GFR (Supplementary Tables 2A and 2B).   
Relationships between individual aminothiols and outcomes 
During a mean follow up of 4.7 (±2.1) years (median 5.3; IQR 3.1 - 6.2), representing 6570 
person-years of follow-up, 247 patients experienced the primary outcome of death, of which 
there were 169 cardiovascular deaths and 314 composite outcomes of death/MI. Patients who 
experienced the primary outcome, were generally older and had more risk factors and disease 
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burden as shown in Table 1.  Independent clinical predictors of outcomes are presented in 
Supplementary Table 3. 
The baseline cystine (p<0.001) and glutathione (p=0.002) levels were both associated 
with risk of future death after adjustment for age and gender (log values, Table 2).  These 
associations persisted after further adjustment for important covariates (see methods) including 
hs-CRP (p=0.001 and p=0.006 respectively).  After standardization, to permit marker 
comparisons, a one SD increment in cystine and a one SD decrease in glutathione was associated 
with a 26% and 20% increase in risk of death after adjustment for all risk factors, respectively, 
Table 2.  
This association was also evident when cystine and glutathione levels were categorized 
into quartiles (Kaplan Meier log rank p<0.001 and p=0.002 respectively; Supplementary Figure 
1 & Supplementary Table 4). Examination of the Kaplan Meier plots revealed a possible 
threshold effect, especially for glutathione.   
We further explored this by using a 1 SD cut point to define high and low levels of 
aminothiol markers (see methods).  Survival analysis confirmed a worse prognosis for patients 
with high cystine (>+1SD; >129.8μM) and for those with low glutathione (<-1SD, <0.68μM) 
levels (log rank p<0.001 for both, Figure 1).  Both a high cystine level and low glutathione level 
were each associated with a 2 to 3-fold increase in age and gender adjusted risk of death (HR 
2.05 (1.53-2.75); 3.16 (2.20-4.54) respectively).  After adjustment for all covariates, a high 
cystine level was associated with a HR of 1.63 (1.19-2.21) and a low glutathione level of 2.19 
(1.50-3.19).  
Importantly, both cystine and glutathione were independently associated with the primary 
outcome of death, when entered into the same multivariate model.  Furthermore, both of these 
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aminothiols were also associated with the secondary outcomes of cardiovascular death and the 
composite of death and MI (Table 2).  Glutathione in particular showed a greater effect size for 
cardiovascular death compared to all-cause death.  However, their respective couples, cysteine 
(reduced) and glutathione disulphide (oxidized) were not associated with the outcomes examined 
(data not shown).  
Relationship between aminothiol ratios and outcomes 
We also examined the ratio of cystine to glutathione, as a novel measure of extracellular 
oxidation to intracellular reducing capacity and demonstrated a highly significant association 
with the primary outcome (p<0.001) (Table 3, Figure 1).  Patients with a >+1SD level of 
cystine/glutathione ratio, reflecting a high extracellular oxidant burden and low intracellular 
reducing capacity, demonstrated a HR of 1.92 (1.39-2.64) for death after full adjustment for all 
covariates (Table 3).  Similar significant associations were noted for the secondary outcomes of 
cardiovascular death (HR 1.91 (1.34-2.72) and the composite of death/MI (HR 1.88 (1.40-2.52)). 
In contrast, although the direct ratios within the extracellular and intracellular 
compartments, of cystine (oxidized) to cysteine (reduced) and glutathione disulphide (oxidized) 
to glutathione (reduced) were associated with the studied outcomes in adjusted models, the 
associations were attenuated compared to those for cystine, glutathione, or the 
cysteine/glutathione ratio (Table 3).   
CAD and MI Subgroup Analyses 
There was no significant heterogeneity in the association between the cystine/glutathione ratio 
and adverse events based on baseline characteristics.  Thus, among patients with obstructive 
CAD, those with high cystine/glutathione ratio had a HR of 1.80 (95% CI 1.27-2.54)) compared 
to 3.11 (95% CI 1.19-8.15) for those with non-obstructive CAD.  While there was no significant 
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interaction, the risk of a high cystine/glutathione ratio was higher in those with acute MI 
compared to those without; HR 3.87 (1.74-8.63) and HR 1.82 (1.26-2.62), respectively. 
Inflammation and oxidant stress 
Given that no significant interaction between hs-CRP and each of the markers (including their 
ratios) was found (results not shown) and both hs-CRP and the cystine/glutathione ratio were 
independently associated with risk of death, we devised a simple multi-marker score, using 
high/low categories to identify the potential value of combining inflammation and OS measures 
for predicting future events.  A score of 0 (n=647) represented both low inflammation (low hs-
CRP, defined as <3mg/L (median))23 and low OS (low cystine/glutathione ratio (by SD as 
above)), while a score of 2 reflected both high hs-CRP and high cystine/glutathione (n=84).  A 
score of 1 was given to the remaining 661 subjects (Figure 2). Compared to those with a score of 
0, those with a score of 1 had a covariate adjusted HR of 1.46 (1.08-1.97) for risk of death while 
those with a score of 2 had a HR of 3.26 (2.17-4.90).  Thus, patients with a score of 0, 1 or 2 
experienced a one year death rate of 1.1%, 4.9% or 14.5% or a 5-year event rate of 9.7%, 17.3% 
and 41.5%, respectively.  
Discrimination testing 
When compared to a standard model for risk of death, consisting of traditional risk factors (see 
methods), the addition of hs-CRP, hs-CRP + the ratio of cystine/glutathione, and the 
combination of these two biomarkers as a multi-marker score improved the risk discrimination 
significantly, including C-statistic, NRI, and IDI (Table 4). Specifically, while addition of the 
individual aminothiols cystine or glutathione did not improve risk discrimination, the ratio of 
cystine/glutathione improved both the NRI (0.109, 95% CI=[0.011, 0.176]) and IDI (0.012, 95% 
CI=[0.001, 0.029]) (Table 4).  
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Discussion
Herein we demonstrate that the plasma aminothiols, cystine and glutathione associate with risk 
of future death in a high risk population with CAD.  This effect is independent of, and additive to 
that of inflammation as assessed by hs-CRP.  Quantification of plasma aminothiol markers may 
thus represent an important advance for in-vivo assessment of clinically important OS.  
Specifically, we show that patients with high OS captured as (1) a high level of oxidized 
cystine, representing greater extracellular oxidant burden, (2) a low level of reduced glutathione, 
representing low intra-cellular reducing capacity, or (3) a high ratio of the two, have a 2-fold 
increase in risk of mortality over a mean of 5 years independent of age and other risk factors 
including inflammation.  While previous attempts at quantifying aminothiol mediated OS have 
utilized the redox potential of cystine or glutathione disulphide using the Nernst equation,6 we 
found that the directly combined, cross compartment ratio of cystine to glutathione is simple and 
practical to calculate and able to discriminate risk, thus representing an improved approach to 
capturing the overall burden of OS in vivo.   
Control of protein redox state via thiol-disulfide switching is critical for normal cellular 
activities and for maintaining physiological and pathophysiological functions including 
promotion of CVD.  This includes (1) experimental evidence for effects on pro-inflammatory 
signalling, mitochondrial oxidation, nuclear factor KB activation and elevated expression of 
genes for monocyte recruitment to endothelial cells;5, 7, 8, 24 (2) association with clinical risk 
factors such as aging, obesity and smoking;9, 25, 26 (3) translational studies confirming association 
between aminothiols and worse endothelial function, carotid intima media thickness and arterial 
stiffness;11, 27, 28 and (4) prospective outcome data in patients at high CVD risk as presented here.  
In totality, these findings support the use of plasma levels of oxidized and reduced aminothiols as 
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key biomarkers of OS and cellular health and potentially as new therapeutic targets. 
The utility of these aminothiols in clinical practice requires further testing.  While 
addition of cystine and glutathione individually did not improve risk discrimination beyond a 
standard clinical model, addition of the cystine/glutathione ratio did improve both risk 
reclassification metrics. Given the interplay between inflammation and OS at a molecular level, 
and with additive effect on risk, we devised and tested a simple multi-marker score combining 
the biomarkers of each, for ease of clinical use.  This simple 3-point score clearly stratified risk 
and when added to a clinical model also improved the C-statistic and metrics of risk 
reclassification. Thus, a combination of biomarkers, in this case reflecting aminothiol mediated 
OS and inflammation quantified by CRP, may offer a valuable approach for clinical risk 
stratification as has been recently described.14   
Mechanistically, these findings may have implications for understanding other 
observations. Homocysteine, an important aminothiol, is biosynthesized from dietary 
methionine, and in the presence of folate and B vitamins converts to cysteine by cystathione 
synthase (Supplementary Figure 2).  While patients with genetic hyperhomocystinemia are 
prone to severe atherosclerosis, folate supplementation and homocysteine reduction does not 
appear to reduce CVD risk.29, 30  This may be because cysteine is independently maintained from 
homocysteine and represents a more abundant and reactive aminothiol that on oxidation forms 
cystine, which is 30-times more abundant than homocysteine and perhaps is a more pathological 
component.  While some studies have shown association between total cysteine and CVD,31, 32 
none until now, have examined the individual oxidized and reduced components or their 
respective contribution to the oxidant burden. This data may thus offer a partial explanation for 
the failure of homocysteine targeted therapy and possible new treatment opportunities.  
 by guest on January 29, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
DOI: 10.1161/CIRCULATIONAHA.115.019790 
14 
Although experimental data supports the role of free radical biology in OS, clinical 
attempts at improving outcomes with free radical scavengers (vitamins C, E etc) have been 
uniformly disappointing.2, 33  Our findings support the hypothesis that in-vivo, OS may also be 
driven by non-free radical processes, raising the possibility that alternative anti-oxidative 
therapies may be more effective.  In humans there is no currently known pathway to reduce 
cystine to cysteine, although cystine levels are in part controlled by the Xc system acting as a 
highly efficient glutamate-cystine transporter.34  Cellular expression of this transporter declines 
with age, potentially explaining the association with cystine and age that we and others have 
observed.  In contrast zinc enhances expression of this system and could represent a therapeutic 
option to reduce plasma cystine and OS. Indeed a recent pilot study in patients with macular 
degeneration has revealed reductions in plasma levels of oxidized cystine with zinc 
supplementation, suggesting that levels can be manipulated with therapeutic interventions.35  
Strengths & Limitations 
Strengths of our study include its prospective design, large sample size, exploration of both 
reduced and oxidized aminothiols, long follow up, use of robust clinical outcomes and 
exploration of the interaction with inflammation assessed by hs-CRP. We did not have dietary 
information on our subjects and ingestion of sulphur-rich amino acids may influence plasma 
aminothiol levels.  However, after a meal, cysteine shows rapid distribution and cystine levels 
increase for 2-3 hrs and almost all of our patients were fasting for >8 hours which minimized the 
likely dietary changes on aminothiol levels.  We did not have detailed drug information to 
explore whether thiol containing medications impacted on measured levels and it is possible that 
some patients taking these drugs may have non representative levels.  Our population is also not 
representative of all populations, and thus our findings may not be generalizable, and require 
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further validation in different groups.   
Finally, as an observational study we cannot infer causality and confounding by CAD 
remains possible.  Nonetheless, oxidative stress is an accepted mechanism for plaque 
development and previous associations with upstream risk factors and subclinical phenotypes in 
those without CAD, as well as sensitivity analysis in those with and without CAD showing a 
consistent effect in both groups, suggests reverse causation is less likely.  However confounding 
can never be fully excluded without interventional studies, but even if causality is not confirmed, 
this does not limit the value of these thiols for use as biomarkers of intracellular and extracellular 
oxidative stress, analogous to use of CRP as a biomarker of systemic inflammation.   
Conclusions and Implications 
A high extracellular oxidant burden and/or reduced intracellular anti-oxidant capacity quantified 
through assessment of plasma aminothiols, is associated with higher mortality in patients with 
CAD.  As well as representing potentially novel therapeutic targets, OS measured in this way 
could complement risk stratification in conjunction with assessment of inflammation assessed by 
hs-CRP.  Further studies will evaluate non-HPLC methods of aminothiol assessments to 
facilitate their wider use as biomarkers and to investigate whether therapies such as zinc 
supplementation, seeking to reduce plasma cystine can alter OS and improve outcomes.    
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Clinical Perspective 
Although oxidative stress is a critically important process in atherosclerosis, observational 
evidence and clinical trials of free radical scavengers have proven unfirmly disappointing.  This 
has promoted the concept that clinically important oxidative stress may be mediated by non-free 
radical species. Proteins with reactive aminothiols are susceptible to oxidation and quantification 
of these reduced and oxidized (redox) residues offers an alternative means of quantifying in-vivo 
oxidative stress and oxidant burden.  Having developed means to reliably collect and quantify 
these markers in plasma, we have previously shown associations with multiple risk factors for 
cardiovascular disease as well as with subclinical markers such as arterial stiffness and intima 
media thickness.  However, whether these markers are clinically relevant has remained 
unknown.  In this study, we now present long term outcome data demonstrating association 
between these redox markers and adverse cardiovascular outcomes and mortality.   These 
findings are important as they support the use of these aminothiols as novel and reliable 
biomarkers of oxidative stress.  Importantly, given that oxidation of these aminothiols leads to 
altered cellular signaling, these findings may offer new opportunities for therapeutic 
interventions for reducing the adverse clinical impact of oxidative stress in vivo.   
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Table 1. Patient Characteristics. 
All (1411) No Event (1164) Event (247) 
Clinical Characteristics    
Age, years 63.2 (11.3) 62.0 (11.1) 69.0 (11.0) 
Male, % 66.3 66.2 66.8 
Caucasian, % 85.7 85.2 88.3 
Body Mass Index (BMI), kg/m2 29.9 (6.41) 30.2 (6.4) 28.5 (6.4) 
GFR, ml/min 73.1 (21.6) 75.3 (20.2) 62.5 (24.6) 
Hypertension, % 68.9 66.9 78.1 
Hyperlipidemia, % 68.4 67.8 71.7 
Total Cholesterol, mg/dL 172.2 (45.7) 174.4 (45.7) 161.4 (44.1) 
LDL, mg/dL 99.6 (38.5) 101.4 (39.2) 91.2 (34.5) 
HDL, mg/dL 41.2 (12.3) 41.4 (12.1) 40.3 (13.2) 
Diabetes mellitus,% 32.2 29.9 43.3 
Current Smoking,% 16.4 16.4 16.6 
Acute MI, % 14.3 13.2 19.8 
LV EF % 53.7 (11.9) 54.9 (10.8) 48.0 (15.3) 
Angiographic CAD    
Significant >50%, % 71.5 69.8 81.9 
Normal <10%, % 19.1 20.9 8.7 
Median Gensini Score (IQR) 14.5 (1-51) 13.0 (0-44) 28 (5-121) 
Revascularization at Enrollment, % 46 44.8 52.5 
Medication use    
Statin use, % 74.4 74.6 73.1 
Aspirin use, % 83 83.4 81.4 
ACE or ARB use, % 62.7 62.3 64.9 
Beta blocker use, % 63.8 62.2 71.5 
Inflammation (median, IQR)    
C-Reactive Protein, mg/L 2.9 (1.2-7.1) 2.6 (1.2-6.4) 4.7 (1.75-14.0) 
Oxidative stress (median, IQR)    
Cystine, μM 97.6 (83.3-115.0) 96.1 (82.3-112.3) 106.9 (90.4-130.6) 
Cysteine,  μM 12.2 (10.1-14.7) 12.2 (10.1-14.4) 12.3 (9.6-16.1) 
Glutathione,  μM 1.17 (0.92-1.47) 1.19 (0.94-1.48) 1.07 (0.82-1.43) 
Glutathione disulphide,  μM 0.02 (0.01-0.03) 0.02 (0.01-0.03) 0.02 (0.02-0.04) 
Mean (SD) values, median (IQR) values and % shown unless stated 
GFR – Glomerular Filtration Rate; MI –Myocardial Infarction; CAD – Coronary Artery Disease; LVEF –Left 
Ventricular Ejection Fraction; LDL – Low Density Lipoprotein; HDL – High Density Lipoprotein 
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Table 2. Cox regression survival analysis for the individual aminothiol markers showing significant association with adverse events*. 
Continuous (log) Standardized (per SD) Categorized (High v Low) 
HR (95% CI) HR (95% CI) HR (95% CI) 
Aminothiol Outcome Age & gender adjusted 
Fully adjusted 
model 
Age & gender 
adjusted 
Fully adjusted 
model 
Age & gender 
adjusted 
Fully adjusted 
model 
Death  
(n=247) 
4.02 (2.38-6.78) 
p<0.001 
2.42 (1.40-4.17) 
p=0.001 
1.44 (1.25-1.64) 
P<0.001 
1.26 (1.09-1.45) 
P=0.001 
2.05 (1.53-2.75) 
P<0.001 
1.63 (1.19-2.21) 
P=0.002 
Cystine
(oxidized)
Death/MI 
(n=314) 
3.15 (1.99-4.99) 
p<0.001 
2.06 (1.28-3.32) 
p=0.003 
1.35 (1.20-1.52 
P<0.001) 
1.21 (1.07-1.37) 
P=0.003 
1.88 (1.44-2.46) 
p<0.001 
1.54 (1.16-2.04) 
p=0.003 
CV Death 
(n=169)  
3.90 (2.07-7.33) 
p<0.001 
2.06 (1.07-3.96) 
p=0.031 
1.42 (1.21-1.68) 
P<0.001 
1.21 (1.02-1.43) 
P=0.031 
2.16 (1.52-3.07) 
p<0.001 
1.63 (1.12-2.36) 
p=0.010 
       
Death  
(n=247) 
1.82 (1.42-2.33) 
P<0.001 
1.57 (1.22-2.02) 
P=0.001 
1.24 (1.08-1.43) 
P=0.002 
1.20 (1.05-1.37) 
P=0.006 
3.16 (2.2-4.54) 
P<0.001 
2.19 (1.50-3.19) 
p<0.001 
Glutathione
(reduced)
Death/MI 
(n=314) 
1.73 (1.38-2.17) 
P<0.001 
1.51 (1.20-1.90) 
P<0.001 
1.23 (1.08-1.39) 
P=0.001 
1.20 (1.06-1.34) 
P=0.003 
2.66 (1.89-3.74) 
p<0.001 
1.89 (1.32-2.70) 
p<0.001 
CV Death 
(n=169)  
1.88 (1.40-2.53) 
P<0.001 
1.63 (1.20-2.20) 
P=0.002 
1.21 (1.03-1.43) 
P=0.023 
1.18 (1.01-1.38) 
P=0.041 
3.63 (2.39-5.50) 
p<0.001 
2.53 (1.63-3.92) 
p<0.001 
Cox regression analysis of aminothiol markers as continuous and categorized measures, with risk of adverse outcomes; Cystine categorized as high if >+1 SD 
and low if ?+1 SD; Glutathione categorized as low if <-1SD and high if ?-1 SD; Cysteine (reduced) and Glutathione disulphide (oxidized) did not show any 
significant associations – data not shown; Full model includes adjustment for age, gender, body mass index, glomerular filtration rate, diabetes, hypertension, 
TC, HDL, current smoking, statin use, acute myocardial infarction, LV EF, Gensini score and LnCRP.  
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Table 3. Cox regression survival analysis for oxidized to reduced ratios of aminothiol markers with the primary outcome of death. 
Continuous (log) Standardized (per SD) Categorized (High v Low) 
HR (95% CI), p value HR (95% CI), p value HR (95% CI), p value 
Aminothiol Ratio Outcome Age & gender adjusted 
Fully adjusted 
model 
Age & gender 
adjusted 
Fully adjusted 
model 
Age & gender 
adjusted 
Fully adjusted 
model 
Death  
(n=247) 
2.16 (1.65-2.82) 
p<0.001 
1.74 (1.34-2.27) 
p<0.001 
1.47 (1.29-1.68) 
P<0.001 
1.32 (1.16-1.50) 
P<0.001 
2.26 (1.65-3.09) 
P<0.001 
1.92 (1.39-2.64) 
p<0.001 
Cystine/Glutathione 
ratio
Death/MI 
(n=314) 
1.97 (1.56-2.49) 
p <0.001 
1.65 (1.31-2.08) 
p <0.001 
1.40 (1.25-1.58) 
P<0.001 
1.29 (1.14-1.44) 
P<0.001 
2.17 (1.63-2.90) 
p<0.001 
1.88 (1.40-2.52) 
P<0.001 
CV Death 
(n=169)  
2.13 (1.59-2.86) 
p<0.001 
1.66 (1.21-2.28) 
p=0.002 
1.45 (1.24-1.71) 
P<0.001 
1.29 (1.10-1.51) 
P=0.002 
2.31 (1.58-3.36) 
p<0.001 
1.91 (1.34-2.72) 
P<0.001 
       
Death  
(n=247) 
1.87 (1.28-2.73) 
p<0.001 
1.50 (1.05-2.15) 
p=0.027 
1.23 (1.09-1.40) 
P=0.001 
1.15 (1.02-1.29) 
P=0.027 
1.72 (1.24-2.39) 
P=0.001 
1.36 (0.97-1.91) 
P=0.07 
Cystine/Cysteine ratio Death/MI (n=314) 
1.78 (1.27-2.51) 
p=0.001 
1.50 (1.08-2.08) 
p=0.015 
1.21 (1.08-1.36) 
P=0.001 
1.14 (1.03-1.28) 
P=0.015 
1.57 (1.15-2.12) 
p=0.004 
1.31 (0.96-1.80) 
P=0.09 
CV Death 
(n=169)  
1.72 (1.09-2.71) 
p=0.021 
1.32 (0.86-2.04) 
P=0.20 
1.20 (1.03-1.39) 
P=0.021 
1.10 (0.95-1.27) 
P=0.20 
1.74 (1.12-2.58) 
p=0.006 
1.30 (0.87-1.95) 
P=0.21 
       
Death  
(n=247) 
1.34 (1.12-1.60) 
p=0.001 
1.21 (1.01-1.46) 
p= 0.035 
1.22(1.10-1.37) 
P=0.001 
1.14 (1.01-1.29) 
P=0.035 
1.59 (1.10-2.29) 
P=0.014 
1.36 (0.93-1.98) 
P=0.111 
Glutathione disulphide/ 
Glutathione ratio 
Death/MI 
(n=314) 
1.41 (1.20-1.65) 
p<0.001 
1.31 (1.12-1.53) 
P=0.001 
1.25 (1.13-1.39) 
P<0.001 
1.20 (1.08-1.33) 
P=0.001 
1.78 (1.29-2.45) 
p<0.001 
1.55 (1.11-2.14) 
P=0.009 
CV Death 
(n=169)  
1.37(1.07-1.699) 
p=0.004 
1.22 (0.98-1.53) 
P=0.07 
1.23 (1.07-1.42) 
P=0.004 
1.14 (0.99-1.32) 
P=0.074 
1.70 (1.10-2.62) 
P=0.017 
1.43 (0.92-2.24) 
p=0.11 
Cox regression analysis of aminothiol marker ratios as continuous and categorized measures, with risk of adverse outcomes; All ratios categorized as high if >+1 
SD and low if ?+1 SD; Full model includes adjustment for age, gender, body mass index, glomerular filtration rate, diabetes, hypertension, TC, HDL, current 
smoking, statin use, acute myocardial infarction, LV EF, Gensini score and LnCRP.  
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Table 4. Estimates and the corresponding 95% confidence limits for the risk discrimination metrics (change in C-statistic, NRI, and 
IDI) for the primary outcome of death within five years of follow up. 
Models C-statistic ? C-statistic Category free NRI Relative IDI 
Clinical Model 0.717 (0.674, 0.761) - - - 
+ CRP 0.736 (0.692, 0.779) 0.018 (0.003, 0.034) 0.109 (0.023, 0.203) 0.0202 (0.006, 0.04) 
+ Cystine (CySS) 0.722 (0.678, 0.766) 0.005 (-0.003, 0.013) 0.046 (-0.041, 0.132) 0.006 (-0.001, 0.020) 
+ Glutathione (GSH) 0.724 (0.688, 0.759) 0.006 (-0.004, 0.017) 0.084 (-0.026, 0.157) 0.005 (-0.001, 0.017) 
+ CySS/GSH Ratio 0.728 (0.695, 0.762) 0.011 (-0.002, 0.024) 0.109 (0.011, 0.176) 0.012 (0.001, 0.029) 
+ CRP + CySS/GSH Ratio 0.746 (0.708, 0.785) 0.029 (0.009, 0.049) 0.133 (0.044, 0.214) 0.032 (0.013, 0.059) 
+ Multi-marker score* 0.736 (0.702, 0.769) 0.018 (0.002, 0.035) 0.124 (0.026, 0.191) 0.018 (0.004, 0.043) 
Clinical Model – includes age; gender; BMI; GFR; diabetes; hypertension; current smoking; acute MI; Gensini score; LV EF; statin use; total cholesterol and 
HDL  
*Multi-marker score is scored 0, 1 and 2 based on combinations of high or low CRP and high or low cystine/glutathione ratio  
NRI = Net Reclassification Improvement; IDI = Integrative Discriminatory Improvement  
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Figure Legends: 
Figure 1. Kaplan Meier curves for association between high v low levels of cystine, glutathione 
and the cystine/glutathione ratio.  High v low categorization was defined by SD cut off (see 
methods). Log rank p values and number of patients within each category is shown.  
 
Figure 2. Covariate adjusted survival analysis for the multi-marker score by cox regression, 
combining low v high hs-CRP (inflammation) and low v high cystine/glutathione ratio 
(Oxidative Stress (OS)).  A score of 0 (blue line, n=647) represents low inflammation and low 
OS, while a score of 2 (red line, n=84) represents high inflammation and high OS. A score of 1 
(green line, n=661) represents either high inflammation or high OS only.  
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Supplementary Methods: Sample collection and storage details.  
 
A full methods paper has been published previously which details each step of the protocol with key 
references and figures to replicate the procedure exactly (Jones 2009).  Abbreviated key details for 
review are provided here: 
 
Collection of samples and processing involves use of 2 sets of microcentrifuge (Eppendorf) tubes 
termed “N” and “S” tubes, prepared in advance and stored at -80C.  The “N” tube consists of L 
serine, heparin, bathophenanthrolene disulfonate, iodoacetic acid in borate buffer with internal 
standard.  Treatment with the first derivatizing agent (to block thiols) occurs during the sample 
collection and is complete by the time the plasma (from N tube) is transferred to S tube. The “S” 
tube contains boric acid in distilled de-ionized water.  
 
Blood is drawn with a syringe through the arterial sheath at the time of catheterization as in this 
study or via butterfly needle if venous cannulation is performed.  Blood is transferred to the “N” tube 
carefully bringing the level up to the 1.5ml line (to account for 1350ul of blood and 150ul of additive). 
The tube is inverted gently and then spun using a centrifuge to remove RBCs. Routine use of this 
method has only identified minor haemolysis in 2 of 600 samples by spectrophotometry. Next, 200ul 
of supernatant is transferred to the “S” tube.  This should be done within 2 minutes after blood 
collection, although 5 minutes is acceptable.  This tube is then inverted gently, labelled and placed 
on ice before transfer to a -80C freezer.  
 
Within 1-2 months, samples are shipped to an onsite laboratory for analysis.  Samples in the “S” 
tubes are thawed and the supernatant transferred to a fresh Eppendorf tube before addition of KOH 
to adjust the pH to 9.0, followed by addition of dansyl chloride.  Chloroform is added to extract 
unreacted dansyl chloride and samples stored again until assay by HPLC, usually within a few days.   
Reproducibility, stability and recovery tests for glutathione have indicated that non-derivatized 
samples stored at -80C were stable for 2 months without significant loss, while dansyl-derivatives 
were stable in the dark at 0-4 degrees for 12 months (Jones 1998).  Similar findings have been 
documented for the cystine pool, with no evidence of loss demonstrated at 12 months (Johnson 
2008).   
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Supplementary Table 1: Correlation coefficients between each of the thiols  
 
 Cystine Cysteine Glutathione 
Glutathione 
disulphide 
C-Reactive 
Protein 
Cystine  0.262 -0.111 0.075 0.057 
Cysteine   0.330 0.095 -0.015 
Glutathione    0.314 -0.025 
Glutathione 
disulphide 
    0.038 
C-Reactive 
Protein 
     
 
 
Spearman Rank coefficients (rho) for correlation between markers
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Supplementary Table 2A: Univariate and multivariate associations between patient characteristics and the cysteine couple 
 
 Cystine Cysteine 
 Univariate Multivariate Univariate Multivariate 
 beta p value beta p value beta p value beta p value 
Age, years 0.30 <0.001 0.164 <0.001 0.08 0.002 0.005 0.89 
Male Gender -0.12 <0.001 -0.095 0.001 -0.04 0.11 -0.056 0.053 
Body Mass Index, kg/m2 0.13 <0.001 0.128 <0.001 -0.01 0.60 -0.016 0.523 
GFR, ml/min -0.39 <0.001 -0.261 <0.001 -0.13 <0.001 -0.115 <0.001 
Acute MI 0.04 0.19 0.012 0.672 0.013 0.62 -0.006 0.79 
Diabetes 0.17 <0.001 0.092 <0.001 0.03 0.20 0.020 0.47 
Hypertension 0.18 <0.001 0.058 0.021 0.04 0.14 0.007 0.82 
Current Smoking -0.11 <0.001 -0.046 0.085 -0.026 0.33 -0.012 0.612 
LV EF, % -0.06 0.02 -0.044 0.042 -0.05 0.054 -0.047 0.099 
Gensini Score (CAD burden) 0.13 <0.001 0.038 0.168 0.09 0.001 0.064 0.044 
Statin use 0.07 0.006 0.008 0.753 0.06 0.022 0.035 0.169 
HDL, mg/dl -0.03 0.33 -0.037 0.31 -0.02 0.52 -0.036 0.197 
Total Cholesterol, mg/dl -0.08 0.003 -0.003 0.80 0.034 0.20 0.072 0.013 
hs-CRP, mg/L (log) 0.06 0.03 -0.001 0.951 -0.01 0.69 -0.039 0.195 
 
Multivariate model - Independent determinants of each aminothiol (natural log transformed), using linear regression with all variables in the left 
column entered into the same model.  GFR – Glomerular Filtration Rate; MI –Myocardial Infarction; CAD – Coronary Artery Disease; LVEF –Left 
Ventricular Ejection Fraction; HDL – High Density Lipoprotein; hs-CRP – high sensitivity C Reactive Protein 
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Supplementary Table 2B: Univariate and multivariate associations between patient characteristics and the glutathione couple 
 
 Glutathione Glutathione disulphide 
 Univariate Multivariate Univariate Multivariate 
 beta p value beta p value beta p value beta p value 
Age, years -0.10 <0.01 -0.072 0.042 0.04 0.12 0.000 0.964 
Male Gender 0.04 0.14 0.029 0.323 0.004 0.89 0.028 0.335 
Body Mass Index, kg/m2 -0.05 0.058 -0.067 0.020 -0.024 0.41 -0.027 0.555 
GFR, ml/min 0.06 0.021 0.037 0.353 -0.077 0.004 -0.074 0.020 
Acute MI 0.08 0.76 0.007 0.810 0.044 0.10 0.037 0.171 
Diabetes -0.08 0.004 -0.039 0.152 -0.013 0.63 -0.006 0.782 
Hypertension -0.09 0.001 -0.041 0.124 0.018 0.51 0.014 0.617 
Current Smoking -0.012 0.66 -0.041 0.122 -0.014 0.60 -0.011 0.735 
LV EF, % -0.015 0.57 -0.029 0.292 -0.021 0.42 -0.013 0.633 
Gensini score (CAD burden) -0.06 0.016 -0.067 0.026 -0.023 0.38 -0.057 0.087 
Statin use 0.014 0.6 0.055 0.052 0.014 0.64 0.032 0.562 
HDL, mg/dl -0.013 0.63 -0.032 0.223 0.035 0.19 0.039 0.168 
Total Cholesterol 0.07 0.008 0.061 0.020 -0.012 0.66 -0.006 0.779 
hs-CRP, mg/L (log) -0.016 0.56 -0.005 0.843 0.037 0.17 0.035 0.242 
 
 
Multivariate model - Independent determinants of each aminothiol (natural log transformed), using linear regression with all variables in the left 
column entered into the same model.  GFR – Glomerular Filtration Rate; MI –Myocardial Infarction; CAD – Coronary Artery Disease; LVEF –Left 
Ventricular Ejection Fraction; HDL – High Density Lipoprotein; hs-CRP – high sensitivity C Reactive Protein 
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Supplementary Table 3: Univariate and multivariate predictors of death 
 
 
 Univariate (beta, p) Multivariate Effect (HR, 95 CI) P value 
Age, years 0.04 (0.008) 1.04 (1.025-1.058) P<0.001 
Male Gender 0.16 (0.15) 1.174 (0.87-1.59) 0.302 
Body Mass Index, kg/m2 -0.025 (0.012) 0.98 (0.95-1.00) 0.049 
GFR, ml/min -0.014 (0.004) 0.986 (0.979-0.993) <0.001 
Acute MI 0.072 (0.170) 1.075 (0.77-1.501) 0.67 
Diabetes 0.47 (0.14) 1.59 (1.21-2.09) 0.001 
Hypertension 0.341 (0.163) 1.406 (1.02-1.94) 0.037 
Current Smoking 0.280 (0.183) 1.32 (0.93-1.89) 0.125 
LV EF, % -0.027 (0.005) 0.97 (0.96-0.98) <0.001 
Gensini score (CAD burden) 0.044 (0.042) 1.05 (0.96-1.14) 0.30 
Statin use -0.290 (0.155) 0.75 (0.55-1.01) 0.061 
HDL, mg/dl 0.001 (0.006) 1.001 (0.989-1.014) 0.84 
Total Cholesterol -0.001 (0.002) 0.99 (0.995-1.002) 0.45 
hs-CRP, mg/L (log) 0.254 (0.052) 1.289 (1.16-1.428) <0.001 
 
 
 
Multivariate model - Independent determinants of death using cox regression with all variables in the left column entered into the same model.  
GFR – Glomerular Filtration Rate; MI –Myocardial Infarction; CAD – Coronary Artery Disease; LVEF –Left Ventricular Ejection Fraction; HDL – High Density 
Lipoprotein; hs-CRP – high sensitivity C Reactive Protein 
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Supplementary Table 4: Cox regression analysis of aminothiol association with death by quartiles 
 
 
  Cystine Glutathione 
  Q4 v Q1 Q1 v Q4 
  HR (95% CI) HR (95% CI) 
Outcome  
Age & gender 
adjusted 
Fully adjusted 
model 
Age & gender 
adjusted 
Fully adjusted 
model 
Death   2.15 (1.39-3.35) 1.82 (1.16-2.86) 1.64 (1.14-2.40) 1.40 (0.97-2.03) 
Death/MI   1.98 (1.37-2.85) 1.72 (1.18-2.51) 1.47 (1.07-2.03) 1.29 (0.93-1.79) 
CV Death   2.05 (1.25-3.39) 1.75 (1.05-2.91) 1.67 (1.11-2.53) 1.42 (0.93-2.16) 
 
Cox regression analysis of aminothiol marker ratios as quartiles, with risk of adverse outcomes; Q1 = lowest quartile and Q4 = highest quartile; 
Full model includes adjustment for age, gender, body mass index, glomerular filtration rate, diabetes, hypertension, TC, HDL, current smoking, 
statin use, acute myocardial infarction, LV EF, Gensini score and LnCRP.  
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Supplementary Figure 1:    Kaplan Meier analysis for cystine and glutathione by quartiles, for association with the primary outcome of Death 
 
 
Cystine (Oxidized) Glutathione (Reduced) 
  
 
10 
 
Supplementary Figure 2: Interplay between homocysteine and cysteine and glutathione 
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Supplementary Figure Legends:  
 
 
Supplementary Figure 1: Kaplan Meier curves for association with quartiles of cystine and 
glutathione; Log rank p values and number of patients within each category is shown.  
 
 
Supplementary Figure 2: Homocysteine pathway - Homocysteine may be converted to 
cystathionine by cystathionine beta synthase.  This in turn may yield cysteine.  Cysteine and 
glutathione may be generated from each other.  As these thiols are reduced (blue) they may 
become oxidized (red) to generate the oxidized thiols cysteine and glutathione disulphide.  
There is no known pathway to reduce these oxidized thiols back to their reduced state.   
MTHFR – methyl tetrahydrofolate reductase; MS - Methionine synthase; CBS – cystathinone 
beta synthase; GSSG – glutathione disulphide; THF – tetrahydrofolate; S-AH – S-adenosyl 
homocysteine; SAM -adenosyl methionine 
 
